António Ferreira
Presidente do Conselho de Administração, Centro Hospitalar Sao João; E.P.E.
Carlos Martins
Presidente do Conselho de Administração, Centro Hospitalar Lisboa Norte, EPE
Iniciou a sua vida profissional em 1985 como responsável pela implementação dos Serviços Sociais do então Instituto Politécnico de Faro, após o que se seguiram vários cargos a nível regional, nacional e internacional, designadamente Autarca no Município de Portimão, Director Regional e Presidente do Instituto da Juventude, Representante de Portugal no Comité de Peritos de Juventude da União Europeia e Perito de Politicas Locais no Conselho da Europa. Em 1999 foi eleito Deputado à Assembleia da República pelo Círculo do Algarve e em anos seguintes foi tomou posse como Secretário de Estado da Saúde e Secretário de Estado adjunto do Ministro do Turismo. De 2005 a 2008 desempenhou funções de administração em holdings e de gestão em empresas nas áreas da Hotelaria e Turismo, Golfe e Imobiliária, Saúde e Bem-estar, Energia e Ambiente, Indústria e Comércio, Comunicação e Eventos, Cooperação e Internacionalização, foi Assessor do Ministro da Saúde para as áreas das Relações Internacionais e Cooperação e em Projectos estratégicos Interministeriais.
É autor de vários artigos sobre desenvolvimento sustentável e poder local, economia social e cooperação internacional, turismo e saúde, destinos emergentes e internacionalização empresarial.
Eduardo Silva
Professor Auxiliar de Oftalmologia, Faculdade de Medicina, Universidade de Coimbra
Eduardo Silva attended medical school in Coimbra, and took His general internship at the University Hospital of Coimbra, immediatly followed by an ophthalmology Residency. He completed his residency in 1997 and moved to Baltimore, MD, USA to join a combined clinical and research fellowship. He obtained his PhD degree from the University of Coimbra in 2003, with a dissertation in transcription factors and eye development. He rejoined faculty at the Department of Ophthalmology of the University Hospital of Coimbra (HUC) and became Assistant Professor of Ophthalmology, at the same University. Since 2006 he is Chief of Pediatric Ophthalmology and Strabismus at HUC and Chief of the Center of Excellence for Hereditary Eye Diseases of the same Department. He is actively involved in training residents and medical students and coordinates a group of scientist involved in basic and clinical ophthalmic research. He is Principal Investigator of several National and International Projects (EVI-Genoret and eRARE) in the areas of retinal dystrophies and eye development. Eduardo Silva has been a Member or belongs to several scientific Boards including EPOS, PSO, Orphanet, Retina Portugal and PAAO. He is a regular reviewer of several publications in Ophthalmology and Genetics and is Section Editor for Vision PanAm. He has received 2 Pfizer Awards and a CGC Award.
Eduardo Silva attended medical school in Coimbra, and took His general internship at the University Hospital of Coimbra, immediatly followed by an ophthalmology Residency. He completed his residency in 1997 and moved to Baltimore, MD, USA to join a combined clinical and research fellowship. He obtained his PhD degree from the University of Coimbra in 2003, with a dissertation in transcription factors and eye development. He rejoined faculty at the Department of Ophthalmology of the University Hospital of Coimbra (HUC) and became Assistant Professor of Ophthalmology, at the same University. Since 2006 he is Chief of Pediatric Ophthalmology and Strabismus at HUC and Chief of the Center of Excellence for Hereditary Eye Diseases of the same Department. He is actively involved in training residents and medical students and coordinates a group of scientist involved in basic and clinical ophthalmic research. He is Principal Investigator of several National and International Projects (EVI-Genoret and eRARE) in the areas of retinal dystrophies and eye development. Eduardo Silva has been a Member or belongs to several scientific Boards including EPOS, PSO, Orphanet, Retina Portugal and PAAO. He is a regular reviewer of several publications in Ophthalmology and Genetics and is Section Editor for Vision PanAm. He has received 2 Pfizer Awards and a CGC Award.
Fernando Royo
Presidente da Fundação Genzyme
Fernando Royo graduated in medicine by Universidad Autónoma de Madrid and holds a master degree in Business Administration by INSEAD in Fontainebleau. Regarding his professional experience, Fernando Royo started his career as a Physician in Spanish National Healthcare System (INSALUD). Between 1982 and 1993, various, and progressively higher, management positions –in the fields of clinical pharmacology, international marketing, strategic planning and business development- in several pharmaceutical multinationals: Boots, Boehringer Ingelheim, Grünenthal and Baxter, at Spanish subsidiaries and Corporate HQ. In 1993 he launched Genzyme Corp. Activities in Spain, establishing and managing later the corresponding Spanish and Portuguese subsidiaries. Since 2008 he is VP International of Government Affairs, while remaining Chairman of the Board in both countries and chairing the Fundación Genzyme. He has been presenter in numerous courses, congresses and symposia, as well as member of various institutional working groups, on healthcare-related biotechnology: orphan drugs/rare diseases, biomaterials and cellular therapies.He’s also a founding member of the Spanish Biotechnology Association (ASEBIO), belonging to its Board since its establishment, and having chaired it from 2001 until 2005.. Since 2007 he is also member of the management board of EUROPABIO, on behalf of ASEBIO.
Francisco Batel Marques
Professor, Faculdade Farmácia da Universidade Coimbra
Hans Schikan
CEO, Prosensa
Hans Schikan is CEO of Prosensa, an innovative Dutch biopharmaceutical company focusing on the discovery, development and commercialization of novel treatments for rare diseases like Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease, using its RNA modulation platform. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme’s portfolio of products for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Next to his role at Prosensa, Hans is currently Executive Board Member of the Dutch Top Institute Pharma, Non-executive Director of Sobi (Swedish Orphan Biovitrum) and Member of the Core Team of the Dutch Top Sector Life Sciences & Health. He is also past Chairman of Nefarma, the Dutch Association of Research Based Pharmaceutical Industry. He has a PharmD from Utrecht University.
Luís Portela
Chairman, BIAL
É licenciado em Medicina pela Universidade do Porto, exerceu atividade clínica no Hospital de S. João apenas durante três anos e foi docente da Universidade do Porto durante seis anos. Desligou-se da carreira de medicina e do ensino e dedicou-se à gestão empresarial. Relativamente à sua carreira empresarial, assumiu o cargo de Presidente dos laboratórios Bial, Presidente do Health Cluster Portugal, foi Presidente do Conselho Geral da Universidade do Porto, Vice-presidente da Fundação de Serralves e membro da Direção da Cotec. A Bial tornou-se a primeira empresa farmacêutica internacional de inovação de origem portuguesa. Em 1994 criou conjuntamente com os Laboratórios Bial e o Conselho de Reitores das Universidades Portuguesas a Fundação Bial. De entre várias condecorações e prémios, Luis Portela é Comendador da Ordem do Mérito, Doutor Honoris Causa pela Faculdade de Medicina de Cádis, Espanha e mais recentemente, em 2013, foi o vencedor do Prémio Excellens Oeconomia, promovido pelo Jornal de Negócios e pela PwC, na vertente “Personalidade do Ano“.
Miguel Forte
Professor Associado, Universidade de Aveiro e Chief Medical Officer da TxCell
Pharmaceutical Industry executive with 20 years experience in performing and leading operational and strategic functions at all stages of medicinal product clinical development from First-in-Man to Commercialization. A strong leader with a team spirit and clear strategic vision. MD specialist in infectious diseases with PhD in immunology and experience in gastroenterology, nephrology, rheumatology, hemato-oncology. Hospital clinical experience in Portugal and UK. Held Academic responsibilities in the Medical Schools of Birmingham, UK and Lisbon, Portugal. Visiting Associate Professor in Drug Clinical Development at University of Aveiro, Portugal. Broad pharmaceutical industry and public sector experience at country, European, US and global levels in the fields of clinical development, regulatory affairs, medical affairs, pharmacoeconomics and medicinal product commercialization. Documented ability to set clear strategic visions and define focused missions on clinical development needs and opportunities for a range of medicinal products including small molecules, vaccines, biologics and cell therapy. Direct experience of leadership and oversight of overall development activities including Pre-Clinical, Process Development, transfer activities and Manufacturing through Project Management. Operational experience and leadership of clinical operations from exploratory to confirmatory phases as well as post-approval. Experience on product launches at country, Europe, US and global levels. Extensive R&D budget management experience with both internal and out-sourced organizations.
Nuno Arantes-Oliveira
Presidente, P-BIO
Nuno Arantes-Oliveira is a life-science expert and serial entrepreneur. He is currently CEO of Coimbra Genomics S.A., a personalized medicine start-up which he co-founded in 2012. Nuno Arantes-Oliveira was President and CEO of Alfama, Inc., a drug development company he also co-founded, he is also President of P-BIO, Portugal’s Biotechnology Industry Organization and was until recently a Board member of the Health Cluster Portugal – the largest association of health-related entities in Portugal.
After graduating from the University of Lisbon in 1997, Nuno entered the Gulbenkian Doctoral Program in Biology and Medicine. He performed his graduate research at the University of California San Francisco (UCSF). From 1998 to 2002 Nuno’s work shed light on the molecular mechanisms controlling lifespan and aging in higher organisms, and led to the publication of several papers in high-impact scientific journals, including three in Science. Nuno Arantes-Oliveira has received awards and decorations from various public and private entities in several countries. He has designed and executed major transactions and collaborations in Europe, North America, China and Africa.
Paula Costa
Presidente, Raríssimas
Presidente da Direcção e fundadora da “ RARÍSSIMAS – Associação Nacional de Deficiências Mentais e Raras”, é também Presidente da Direcção da FEDRA – Federação das Doenças Raras de Portugal e sua fundadora. É impulsionadora da realização do Plano Nacional das Doenças Raras, e principal Incentivadora do Movimento das Doenças Raras em Portugal, com inicio em 2002 em Portugal e no Brasil 2011. Paula Costa é também consultora do movimento associativo e para as questões dos medicamentos órfãos no Brasil desde 2010, criadora do modelo empresarial para associações de doentes, da publicação científica “Doenças Raras de A a Z” e do Modelo Assistencial da Casa dos Marcos – para portadores de Doenças Raras, com empreitada em fase final de construção; É frequentemente convidada para oradora. Tendo participado em mais de 80 congressos a nível nacional e internacional, sobre doenças raras, implementação de políticas de saúde, e boas práticas no movimento associativo.
Rogério Gaspar
Professor, Faculdade de Farmácia
Foi coordenador do Departamento de Farmácia Galénica e Tecnologia Farmacêutica da FFUL e do grupo de investigação “Nanomedicine & Drug Delivery Systems” A sua área de investigação primária é a de desenvolvimento de sistemas terapêuticos à escala nanométrica (nanomedicamentos), tendo sido ainda responsável pela coordenação de projetos com a indústria na área da tecnologia farmacêutica. Atualmente a sua investigação está mais centrada na área oncológica e na modulação do transporte intracelular de moléculas farmacologicamente ativas incluindo ácidos nucleicos. Ocupou diversas posições como perito e responsável institucional no INFARMED e na Agência Europeia do Medicamento na área da regulação do medicamento, a nível nacional e europeu, Ocupou durante algum tempo a posição de perito técnico na área diplomática, exercido na REPER em Bruxelas, bem como de coordenador do grupo de trabalho do Conselho Europeu responsável pela Diretiva Europeia dos Ensaios Clínicos (1999-2000).
